Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Sep
17
2021
SAFE Banking Act of 2021: Where Are We on Cannabis Banking Change? Sheppard, Mullin, Richter & Hampton LLP
Dec
13
2021
Health Law Policy Heading Into 2022 At The ABA Health Law Summit Sheppard, Mullin, Richter & Hampton LLP
Jan
10
2022
CMS’ Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Sheppard, Mullin, Richter & Hampton LLP
Jan
13
2022
Day Three Notes for the 40th Annual J.P. Morgan Healthcare Conference, 2022 Sheppard, Mullin, Richter & Hampton LLP
Apr
12
2022
No April Fools: Starting April 1st, Cannabis Operators Face CEQA Compliance Requirements for State Licenses Sheppard, Mullin, Richter & Hampton LLP
Jul
5
2022
Recap of AHLA’s Annual Meeting Sheppard, Mullin, Richter & Hampton LLP
Jul
12
2019
Regulating E-Cigarettes Remains “Top Priority” For FDA Sheppard, Mullin, Richter & Hampton LLP
Oct
12
2015
Next Rx: New Medicare Part D Initiative Advances Role of Medication Management in Reform Sheppard, Mullin, Richter & Hampton LLP
Jun
16
2023
DOJ Continues to Discuss Updates to Compliance Program Guidance and Corporate Enforcement Policies Sheppard, Mullin, Richter & Hampton LLP
Dec
13
2019
340B Program-Participating Hospitals Object to CMS’s Proposed Cuts to 340B Program Reimbursement: CMS’s Recent Information Collection Request Sheppard, Mullin, Richter & Hampton LLP
Oct
17
2023
Tele-Prescribing Flexibilities Extended Again in Second Temporary Rule Sheppard, Mullin, Richter & Hampton LLP
Nov
21
2023
Voluntary Self-Disclosure of FCPA Violations Following Acquisition Avoids Corruption Charges Sheppard, Mullin, Richter & Hampton LLP
Apr
18
2024
Health-e Law Episode 8: What We Heard at HIMSS 2024 with Michael Orlando & Carolyn Metnick [Podcast] Sheppard, Mullin, Richter & Hampton LLP
Sep
8
2020
New Proposed Regulation Provides More Guidance and Some Relief on Prop 65 Warning Requirements for Heat Processed Foods and Acrylamide Sheppard, Mullin, Richter & Hampton LLP
Sep
14
2020
Trade Secret Protection & the COVID-19 Cure: Observations on Federal Policy-Making & Potential Impact on Biomedical Advances Sheppard, Mullin, Richter & Hampton LLP
Apr
5
2017
New York AG Takes Enforcement Action Against Heart Monitoring Apps: Murmurs of Concern are Heard in mHealth App World Sheppard, Mullin, Richter & Hampton LLP
Mar
11
2021
DFEH Issues Guidance to Employers Regarding Mandatory COVID-19 Vaccination Policies Sheppard, Mullin, Richter & Hampton LLP
Jun
10
2011
Superior Court's Injunction Preventing California's Cap and Trade Program Has Been Stayed...Right? Sheppard, Mullin, Richter & Hampton LLP
Jun
28
2013
Recent Federal and International Developments Good for California Cap and Trade Sheppard, Mullin, Richter & Hampton LLP
Dec
13
2021
Debate Continues Around Scope of Practice Expansion for APPs Sheppard, Mullin, Richter & Hampton LLP
Apr
18
2022
Sow What Now?: Cal. Hispanic Chambers of Commerce et. al. v. Ross et. al., The U.S. Supreme Court, and California’s Proposition 12 Sheppard, Mullin, Richter & Hampton LLP
Mar
2
2019
The Farm Bill’s Impact on Hemp and CBD – and How Some States are Reacting Sheppard, Mullin, Richter & Hampton LLP
Jul
5
2022
CMS Adopts Major Changes to LTC Facility Surveyor Guidance Sheppard, Mullin, Richter & Hampton LLP
Sep
30
2019
New Set Of Guidance From FDA Provides Clarity On Digital Health Policies, Machine Learning Sheppard, Mullin, Richter & Hampton LLP
Jun
13
2023
Don’t Forget Deception: FTC and Biometrics Sheppard, Mullin, Richter & Hampton LLP
Jul
13
2023
The Ninth Circuit Declares that Ambiguity can be Cured with Back Label Sheppard, Mullin, Richter & Hampton LLP
Jul
27
2023
FDA Maintains Focus on “Intended Use” for Software-Enabled Medical Devices Sheppard, Mullin, Richter & Hampton LLP
Mar
25
2020
Top 10 Questions Asked By Medical Group Clients In Response To COVID-19 Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins